Siqing Fu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3321238/publications.pdf

Version: 2024-02-01

171 papers	7,947 citations	53794 45 h-index	60623 81 g-index
177 all docs	177 docs citations	177 times ranked	12627 citing authors

#	Article	IF	Citations
1	Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. Clinical Genitourinary Cancer, 2022, 20, e16-e24.	1.9	1
2	Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study. Investigational New Drugs, 2022, 40, 124-133.	2.6	2
3	Phase 1 trial of ADIâ€PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors. Cancer Medicine, 2022, 11, 340-347.	2.8	13
4	Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. Journal of Clinical Oncology, 2022, 40, 2568-2577.	1.6	18
5	Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences. Scientific Reports, 2022, 12, .	3.3	7
6	Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. JCO Precision Oncology, 2022, , .	3.0	15
7	Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. Molecular Cancer Research, 2021, 19, 395-402.	3.4	7
8	Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptorâ˜positive Metastatic Breast Cancer or Other Solid Tumors. Clinical Cancer Research, 2021, 27, 1247-1255.	7.0	5
9	Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies. British Journal of Cancer, 2021, 124, 1533-1539.	6.4	20
10	Associations between the gut microbiome and fatigue in cancer patients. Scientific Reports, 2021, 11, 5847.	3.3	24
11	Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. Npj Precision Oncology, 2021, 5, 21.	5.4	12
12	Overview of Ocular Side Effects of Selinexor. Oncologist, 2021, 26, 619-623.	3.7	5
13	Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. Oncologist, 2021, 26, 588-596.	3.7	42
14	Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens. Journal of Immunotherapy and Precision Oncology, 2021, 4, 45-52.	1.4	5
15	A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies. Scientific Reports, 2021, 11, 22355.	3.3	5
16	Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory. , 2020, 8, e000931.		11
17	Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clinical Cancer Research, 2020, 26, 1924-1931.	7.0	50
18	Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Scientific Reports, 2020, 10, 3080.	3.3	10

#	Article	IF	Citations
19	Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. Experimental Hematology and Oncology, 2020, 9, 7.	5.0	11
20	Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Dysfunction. Journal of Clinical Pharmacology, 2019, 59, 1204-1215.	2.0	3
21	Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. Journal of Hematology and Oncology, 2019, 12, 145.	17.0	35
22	Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. Journal of Medical Internet Research, 2019, 21, e10348.	4.3	13
23	Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. British Journal of Cancer, 2018, 118, 763-769.	6.4	28
24	Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. Lung Cancer, 2018, 120, 137-141.	2.0	29
25	Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. British Journal of Cancer, 2018, 118, 1419-1424.	6.4	7
26	Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. Clinical Cancer Research, 2018, 24, 181-188.	7.0	127
27	Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. Investigational New Drugs, 2018, 36, 416-423.	2.6	17
28	Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. Investigational New Drugs, 2018, 36, 601-607.	2.6	90
29	Phase I Dose-Escalation Study of Antiâ€“CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers. Molecular Cancer Therapeutics, 2018, 17, 671-676.	4.1	33
30	Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Investigational New Drugs, 2018, 36, 638-646.	2.6	149
31	A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement. Cancer Chemotherapy and Pharmacology, 2018, 82, 877-885.	2.3	5
32	A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. Cancer Chemotherapy and Pharmacology, 2018, 82, 407-418.	2.3	46
33	Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy. Expert Opinion on Investigational Drugs, 2018, 27, 741-751.	4.1	43
34	Outcome analysis of Phase I trial patients with metastaticKRASand/orTP53mutant non-small cell lung cancer. Oncotarget, 2018, 9, 33258-33270.	1.8	9
35	Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience. Investigational New Drugs, 2017, 35, 59-67.	2.6	10
36	Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. Clinical Cancer Research, 2017, 23, 5648-5656.	7.0	50

#	Article	IF	Citations
37	Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. Clinical Cancer Research, 2017, 23, 4155-4162.	7.0	4
38	Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation. Clinical Cancer Research, 2017, 23, 6541-6554.	7.0	27
39	Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Scientific Reports, 2017, 7, 15963.	3.3	21
40	Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors. Investigational New Drugs, 2017, 35, 616-626.	2.6	22
41	Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. , 2017, 5, 35.		58
42	Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. Oncology, 2017, 92, 14-20.	1.9	3
43	Outcomes of patients â‰¥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER. International Journal of Cancer, 2017, 140, 208-215.	5.1	7
44	Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clinical Cancer Research, 2017, 23, 1388-1396.	7.0	261
45	Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. , 2017, 5, 100.		114
46	Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. JCO Precision Oncology, 2017, 2017, 1-18.	3.0	107
47	First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight, 2017, 2, .	5.0	26
48	Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget, 2017, 8, 33796-33806.	1.8	5
49	Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget, 2017, 8, 87163-87173.	1.8	0
50	Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Scientific Reports, 2016, 6, 35448.	3.3	12
51	Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Medicine, 2016, 5, 3437-3444.	2.8	20
52	Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. Cancer Research, 2016, 76, 3690-3701.	0.9	203
53	Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 2016, 77, 1097-1102.	2.3	5
54	Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. Cancer Chemotherapy and Pharmacology, 2016, 77, 973-977.	2.3	34

#	Article	IF	Citations
55	Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment. British Journal of Clinical Pharmacology, 2016, 82, 728-738.	2.4	38
56	TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. Molecular Cancer Therapeutics, 2016, 15, 2475-2485.	4.1	73
57	Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for earlyâ€phase oncology clinical trials. Cancer, 2016, 122, 3401-3409.	4.1	50
58	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discovery, 2016, 6, 1352-1365.	9.4	192
59	BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Molecular Cancer Therapeutics, 2016, 15, 1397-1404.	4.1	78
60	Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 2016, 77, 575-581.	2.3	7
61	Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. Cancer Chemotherapy and Pharmacology, 2016, 77, 357-364.	2.3	4
62	An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. Expert Opinion on Investigational Drugs, 2016, 25, 15-30.	4.1	8
63	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget, 2016, 7, 67521-67531.	1.8	44
64	Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget, 2016, 7, 23227-23238.	1.8	23
65	Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget, 2016, 7, 35132-35143.	1.8	9
66	Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience. Gynecologic Oncology Research and Practice, 2015, 2, 10.	3.6	11
67	Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget, 2015, 6, 12809-12821.	1.8	86
68	Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy. Expert Opinion on Therapeutic Targets, 2015, 19, 1307-1317.	3.4	36
69	Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. BMC Cancer, 2015, 15, 713.	2.6	43
70	The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab. Oncologist, 2015, 20, 737-741.	3.7	11
71	Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines. Supportive Care in Cancer, 2015, 23, 2649-2654.	2.2	26
72	Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Annals of Oncology, 2015, 26, 1012-1018.	1.2	56

#	Article	IF	Citations
73	Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. Investigational New Drugs, 2015, 33, 215-224.	2.6	8
74	A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. Investigational New Drugs, 2015, 33, 177-186.	2.6	25
75	Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. Clinical Cancer Research, 2015, 21, 4801-4810.	7.0	63
76	Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. Investigational New Drugs, 2015, 33, 700-709.	2.6	12
77	Phase I trial of valproic acid and lenalidomide in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 2015, 75, 869-874.	2.3	26
78	Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Investigational New Drugs, 2015, 33, 621-631.	2.6	63
79	Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. Clinical Epigenetics, 2015, 7, 29.	4.1	13
80	Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. Investigational New Drugs, 2015, 33, 911-920.	2.6	7
81	MET Abnormalities in Patients With Genitourinary Malignancies and Outcomes With c-MET Inhibitors. Clinical Genitourinary Cancer, 2015, 13, e19-e26.	1.9	18
82	Prospective study comparing outcomes in patients with advanced malignancies on molecular alteration-matched versus non-matched therapy.. Journal of Clinical Oncology, 2015, 33, 11019-11019.	1.6	8
83	Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget, 2015, 6, 20099-20110.	1.8	41
84	A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. Oncotarget, 2015, 6, 18693-18706.	1.8	24
85	Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget, 2015, 6, 28453-28462.	1.8	9
86	BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget, 2015, 6, 26886-26894.	1.8	45
87	Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors. International Journal of Clinical Pharmacology and Therapeutics, 2015, 53, 563-572.	0.6	8
88	Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents. Molecular Cancer Therapeutics, 2014, 13, 3175-3184.	4.1	31
89	Analysis of 1,115 Patients Tested for MET Amplification and Therapy Response in the MD Anderson Phase I Clinic. Clinical Cancer Research, 2014, 20, 6336-6345.	7.0	70
90	Synergy Between VEGF/VEGFR Inhibitors and Chemotherapy Agents in the Phase I Clinic. Clinical Cancer Research, 2014, 20, 5956-5963.	7.0	10

#	Article	IF	Citations
91	Incidence of Mucositis in Patients Treated With Temsirolimusâ€Based Regimens and Correlation to Treatment Response. Oncologist, 2014, 19, 426-428.	3.7	12
92	Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors. Cell Reports, 2014, 6, 377-387.	6.4	210
93	Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. Investigational New Drugs, 2014, 32, 279-286.	2.6	14
94	Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemotherapy and Pharmacology, 2014, 73, 495-501.	2.3	46
95	Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors. Investigational New Drugs, 2014, 32, 154-159.	2.6	8
96	Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit. Clinical Breast Cancer, 2014, 14, 468-474.	2.4	29
97	Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses. Clinical Cancer Research, 2014, 20, 4827-4836.	7.0	186
98	Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. Investigational New Drugs, 2014, 32, 465-472.	2.6	31
99	Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy. Investigational New Drugs, 2014, 32, 717-722.	2.6	3
100	Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer, 2014, 120, 2164-2173.	4.1	27
101	MABp1, a first-in-class true human antibody targeting interleukin-1Î± in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncology, The, 2014, 15, 656-666.	10.7	178
102	Phase I Clinical Trial of Bendamustine and Bevacizumab for Patients With Advanced Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 194-203.	4.9	4
103	Dual EGFR Inhibition in combination with anti-VEGF treatment in colorectal cancer. Oncoscience, 2014, 1, 540-549.	2.2	22
104	Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. Oncotarget, 2014, 5, 3029-3038.	1.8	40
105	MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget, 2014, 5, 1837-1845.	1.8	27
106	Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. Oncotarget, 2014, 5, 1846-1855.	1.8	28
107	Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms. Oncotarget, 2014, 5, 2349-2354.	1.8	54
108	Characteristics and survival of patients with advanced cancer and p53 mutations. Oncotarget, 2014, 5, 3871-3879.	1.8	11

#	Article	IF	Citations
109	Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget, 2014, 5, 8937-8946.	1.8	6
110	Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. Oncotarget, 2014, 5, 11168-11179.	1.8	53
111	Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program. Anticancer Research, 2014, 34, 2349-55.	1.1	8
112	Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. Cancer Chemotherapy and Pharmacology, 2013, 71, 389-397.	2.3	13
113	PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials. Cancer Research, 2013, 73, 276-284.	0.9	262
114	Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Investigational New Drugs, 2013, 31, 1192-1200.	2.6	51
115	Retreatment after Secondary Resistance or Mixed Response: A Pilot Study. Oncology, 2013, 85, 350-355.	1.9	4
116	Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial. Clinical Cancer Research, 2013, 19, 5474-5484.	7.0	72
117	Barriers to Study Enrollment in Patients With Advanced Cancer Referred to a Phase I Clinical Trials Unit. Oncologist, 2013, 18, 1315-1320.	3.7	20
118	Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA Mutations. Molecular Cancer Therapeutics, 2013, 12, 2857-2863.	4.1	42
119	Reply to M. Rouanne et al. Journal of Clinical Oncology, 2013, 31, 818-818.	1.6	0
120	Combining Erlotinib and Cetuximab Is Associated with Activity in Patients with Nonâ€“Small Cell Lung Cancer (Including Squamous Cell Carcinomas) and Wild-Type EGFR or Resistant Mutations. Molecular Cancer Therapeutics, 2013, 12, 2167-2175.	4.1	33
121	Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells. Frontiers in Oncology, 2013, 3, 58.	2.8	23
122	MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. Oncoscience, 2013, 1, 5-13.	2.2	25
123	Germline PTPRD Mutations in Ewing Sarcoma: Biologic and Clinical Implications. Oncotarget, 2013, 4, 884-889.	1.8	24
124	Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population. Oncotarget, 2013, 4, 772-784.	1.8	16
125	Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer. Oncotarget, 2013, 4, 118-127.	1.8	33
126	Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials. Oncotarget, 2013, 4, 153-162.	1.8	31

#	Article	IF	Citations
127	P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy. Oncotarget, 2013, 4, 705-714.	1.8	96
128	Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience. Clinical Cancer Research, 2012, 18, 2922-2929.	7.0	78
129	Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3. Cancer Biology and Therapy, 2012, 13, 1034-1041.	3.4	13
130	Role of the Human High-Affinity Copper Transporter in Copper Homeostasis Regulation and Cisplatin Sensitivity in Cancer Chemotherapy. Cancer Research, 2012, 72, 4616-4621.	0.9	85
131	Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative. Clinical Cancer Research, 2012, 18, 6373-6383.	7.0	458
132	Mechanistic Basis for Overcoming Platinum Resistance Using Copper Chelating Agents. Molecular Cancer Therapeutics, 2012, 11, 2483-2494.	4.1	67
133	Advance Care Planning in Patients With Cancer Referred to a Phase I Clinical Trials Program: The MD Anderson Cancer Center Experience. Journal of Clinical Oncology, 2012, 30, 2891-2896.	1.6	25
134	Overcoming Platinum Resistance through the Use of a Copper-Lowering Agent. Molecular Cancer Therapeutics, 2012, 11, 1221-1225.	4.1	70
135	Phase I Study of the Antiangiogenic Antibody Bevacizumab and the mTOR/Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin: Tolerance and Biological Activity. Clinical Cancer Research, 2012, 18, 5796-5805.	7.0	77
136	Outcomes in 144 Patients With Colorectal Cancer Treated in a Phase I Clinic: The MD Anderson Cancer Center Experience. Clinical Colorectal Cancer, 2012, 11, 297-303.	2.3	6
137	Evaluation of the Clinical Relevance of Body Composition Parameters in Patients With Cancer Metastatic to the Liver Treated With Hepatic Arterial Infusion Chemotherapy. Nutrition and Cancer, 2012, 64, 206-217.	2.0	29
138	Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors. Clinical Cancer Research, 2012, 18, 2625-2631.	7.0	184
139	PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations. Journal of Clinical Oncology, 2012, 30, 777-782.	1.6	414
140	Safety, pharmacokinetics, and activity of EZNâ€2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. Cancer, 2012, 118, 6144-6151.	4.1	42
141	Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecologic Oncology, 2012, 126, 47-53.	1.4	74
142	Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center. Cancer, 2012, 118, 1422-1428.	4.1	88
143	KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors. PLoS ONE, 2012, 7, e38033.	2.5	44
144	PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes. Oncotarget, 2012, 3, 1566-1575.	1.8	79

#	Article	IF	Citations
145	Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis. Hepato-Gastroenterology, 2012, 59, 960-4.	0.5	2
146	PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers. PLoS ONE, 2011, 6, e22769.	2.5	174
147	PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors. Molecular Cancer Therapeutics, 2011, 10, 558-565.	4.1	311
148	Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement. Cancer Chemotherapy and Pharmacology, 2011, 68, 247-253.	2.3	22
149	Phase 1bâ€2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinumâ€resistant or platinumâ€refractory epithelial ovarian cancer. Cancer, 2011, 117, 1661-1669.	4.1	156
150	Prevalence of complementary medicine use in a phase 1 clinical trials program. Cancer, 2011, 117, 5142-5150.	4.1	53
151	Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albuminâ€“Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity. Molecular Cancer Therapeutics, 2011, 10, 1300-1307.	4.1	22
152	Outcome Analyses After the First Admission to an Intensive Care Unit in Patients With Advanced Cancer Referred to a Phase I Clinical Trials Program. Journal of Clinical Oncology, 2011, 29, 3547-3552.	1.6	28
153	Outcomes of Research Biopsies in Phase I Clinical Trials: The MD Anderson Cancer Center Experience. Oncologist, 2011, 16, 1292-1298.	3.7	60
154	Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. Cancer Chemotherapy and Pharmacology, 2010, 66, 1087-1093.	2.3	17
155	A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5â€fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. Cancer, 2010, 116, 4086-4094.	4.1	26
156	Development of curcumin as an epigenetic agent. Cancer, 2010, 116, 4670-4676.	4.1	146
157	Patients with Advanced Head and Neck Cancers Have Similar Progression-Free Survival on Phase I Trials and Their Last Food and Drug Administrationâ€“Approved Treatment. Clinical Cancer Research, 2010, 16, 4031-4037.	7.0	15
158	Exploratory Study of Hepatic Arterial Infusion Oxaliplatin With Systemic 5-Fluorouracil/Bevacizumab in Patients With Refractory Solid Tumor and Extensive Liver Metastases. Clinical Colorectal Cancer, 2010, 9, 311-314.	2.3	8
159	Nuclear cyclin B1 is overexpressed in low-malignant-potential ovarian tumors but not in epithelial ovarian cancer. American Journal of Obstetrics and Gynecology, 2009, 201, 367.e1-367.e6.	1.3	8
160	The changing face of Phase 1 cancer clinical trials. Cancer, 2009, 115, 1592-1597.	4.1	19
161	Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. American Journal of Obstetrics and Gynecology, 2009, 200, 177.e1-177.e9.	1.3	50
162	Abstract B134: PIK3CA mutations in patients with advanced cancers treated in phase I clinical trials. , 2009, , .		2

#	Article	IF	Citations
163	Diammine Dicarboxylic Acid Platinum Enhances Cytotoxicity in Platinum-Resistant Ovarian Cancer Cells through Induction of Apoptosis and S-Phase Cell Arrest. Pharmaceutical Research, 2008, 25, 2272-2282.	3.5	6
164	Update on Aurora Kinase Inhibitors in Gynecologic Malignancies. Recent Patents on Anti-Cancer Drug Discovery, 2008, 3, 162-177.	1.6	5
165	Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction. Gynecologic Oncology, 2007, 106, 375-380.	1.4	9
166	Proteomics in Gynecologic Malignancies. American Journal of Cancer, 2006, 5, 299-317.	0.4	0
167	Clinical application of oxaliplatin in epithelial ovarian cancer. International Journal of Gynecological Cancer, 2006, 16, 1717-1732.	2.5	26
168	Targeting Aurora kinases in ovarian cancer. Expert Opinion on Therapeutic Targets, 2006, 10, 77-85.	3.4	23
169	Molecular approaches to the diagnosis and treatment of cancer. Stem Cells, 1993, 11, 129-130.	3.2	1
170	Use of Retroviral Markers to Identify Efficacy of Purging and Origin of Relapse Following Autologous Bone Marrow and Peripheral Blood Cell Transplantation in Indolent B Cell Neoplasms (Follicular) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 46 Anderson Cancer Center. Human Gene Therapy, 1993, 4, 821-834.	2.7	9
171	Genetic Therapy of Human Neoplastic Disease. Stem Cells and Development, 1993, 2, 373-375.	1.0	0